3Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J Clin,2011,61 (2) :69-90.
4Lee JH, Choi MS, Gwak GY, et al. Clinicopathologic characteris- tics and long-term prognosis of scirrhous hepatocellular carcinoma [J]. Dig Dis Sci,2012,57(6) :1698-1707.
5Mendez-S6nchez N, Vasquez-Fernandez F, Zamora-Valds D, et al. Sorafenib, a system ic therapy for hepatocellular carcinoma[ J ]. Ann Hepato1,2008,7 ( 1 ) :46-51.
6Yu X, Xia W, Zhang T, et al. Enhanced cytotoxicity of IL-24 gene modified dendritic ceils co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells [ J]. Int J Hematol, 2010,92(2) :276-282.
7Lin G, Wang J, Lao X, et al. Interleukin-6 inhibits regulatory T cells and improves the proliferation and eytotoxic activity of eyto- kine-induced killer eells[J]. J Immunother,2012,35(4) :337-343.
9Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective[ J]. Oncologist, 2010, 15 (Suppl 4) :5-13.
10Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61 ( 2 ) : 69 -90.
